The market of "taking medicine and injecting" in 2021 is entering the end
This week, everyone's attention is focused on the continuous breaks after the first day of listing of new stocks, but there are four on Wednesday, and only one is broken on the first day, but counting the new stocks listed in the past five days, 8 new stocks have fallen below the issue price on Wednesday. This "continuous wave of new stock breaks" has had a great negative impact on A shares. Among them, 349 pharmaceutical and medical stocks have fallen, and the pharmaceutical manufacturing and medical industry index has broken down the support point of nearly six months in 2021 and entered the door of the bear market!
First, the medical market has been falling below the annual line for many consecutive days
Due to the epidemic in the past two years, "medical stocks" have been "big speculation" by large funds, from Kanghua Biology, which stepped onto 999 yuan last year, to Yiqiao Shenzhou, which was issued at a high premium of 292 yuan this year, this specialty super bull plate has always been favored by everyone. However, the author first found today that the sector index has fallen below the annual line after the inability to reverse, and on Wednesday it was even more open to break through the previous low. The net outflow of main funds was 3.69 billion yuan and 1.69 billion yuan respectively. The moving average on the daily chart has shown a clear bearish arrangement.
Second, the stock price of "super high-performing medical stocks" has fallen and fallen in the past six months
In the past few years, everyone attaches great importance to the operating performance of listed companies, and the monthly performance of stock prices is basically commensurate. However, in the past two years, A shares have only speculated in "concepts", and those medical and pharmaceutical stocks that have very beautiful performance in the middle and quarterly reports have done the opposite. Taking the latest announcement of the interim report and quarterly report as the standard, the stock prices of 5 dynamic P/E ratios of less than 3.8 times of Zhonghong Medical, Lanfan Medical, Yingke Medical, Oriental Biology and Heatscape Biology have been falling continuously in the past six months, and on Wednesday, Zhonghong Medical and Heatscape Biological still fell by 10.32% and 7.34% respectively. Have so many institutions not discovered such "value investment stocks"?
Third, the sharp decline in volume indicates that mainstream funds have been cashed out at a high level
The pharmaceutical industry plunged 2.5%, with a turnover of 41 billion yuan and a net outflow of 3.69 billion yuan of main funds. The medical industry plunged 2.3%, with a turnover of 24.3 billion yuan and a net outflow of 1.69 billion yuan of main funds. Tomorrow, Chengda Bio will be issued and listed at a high premium of 110 yuan, and it is estimated that it will not only fall below the issue price, but also fall by about 15%.
The market will go wrong in the short term, but the long-term direction will not deceive people. The market of "taking medicine and injecting" has entered the end!
Communication generates value and listens to risk aversion. Reveal market opportunities for retail investors.
Welcome to click "Follow" and "Comment Exchange Like". (The article clicked on statistics after the release of Oriental Wealth at 9am on Thursday)